AL-SHADOWDRAGON
14.4.2024 18:01:30 CEST | Business Wire | Press release
ShadowDragon™, a provider of ethical open-source intelligence (OSINT) software, unique datasets and APIs, is pleased to announce significant enhancements to its flagship Open-Source Intelligence Investigative platform Horizon®. These updates represent a milestone in the evolution of investigative technology, offering capabilities to streamline investigative processes and uncover valuable insights.
The OSINT Platform encompasses an all-in-one solution for investigations with unparalleled access to publicly available information, including geolocation data, platform monitoring, breach data and the ability to integrate external data streams. This allows for a modern approach to link analysis in one comprehensive toolkit. Horizon® offers access to more than 225 data collection sources, more than 1500 pivot points, and advanced, customizable link analysis capabilities.
Horizon® is accessible with any internet connection and allows users to access critical data and conduct investigations from any device, providing unprecedented flexibility and mobility. Mapping advancements, plotting capability, visual geofencing, and geoestimation allow for different starting points that pinpoint precise locations and uncover valuable insights. Horizon® offers unmatched ease of integration, creating tailored data streams able to solve for any problem set. Horizon® will also enable analysts the ability to work on the go from a tablet, phone, or desktop/laptop.
Horizon®, coupled with ShadowDragon’s SocialNet ® offers a powerful OSINT toolkit that includes more than 225 data collection sources to use for correlating publicly available data, integrated brand monitoring, breach data inquiries, social media information and link analysis capabilities to empower users with a holistic approach to investigations. Users benefit from advanced link analysis capabilities, allowing them to connect the dots and uncover actionable intelligence with ease.
CEO Daniel Clemens said, “Our customers have asked for a unified platform for many years. We are answering their requests with Horizon®, enabling customers to use our platform and data with their existing tools, easily import and export data, while enabling greater focus for complex analysis of data. The Horizon® Platform allows publicly available data to tell the story for the analyst. I am very delighted at what our team has produced and thankful to how our tools help protect many on a global scale.”
“You guys are doing incredible things with SocialNet® and Horizon®. Looking back as a user of Horizon's early release, it has been the coolest privilege to experience the last three years of innovation, watching the platform evolve and morph with every incremental update, and knowing there are always more tweaks still in the works.” - Law Enforcement Customer.
These updates underscore ShadowDragon's commitment to innovation and excellence in the field of investigative technology. By continuously enhancing its OSINT suite with new features, data collection sources and capabilities, ShadowDragon aims to empower investigators with the tools they need to stay ahead of emerging threats and make informed decisions.
Nico Dekens, ShadowDragon Director of Intelligence, said, "This is as close as one can get to having a silver bullet solution that helps solve investigative and analytical needs. This means that no matter what OSINT expertise you have, ShadowDragon's technology will speed up your investigation through an initiative platform. But it is not limited to just the platform and tools, the seasoned team will train you on usage and will support you in getting the most out of your investigative needs. The newly released features and capabilities will make your work future proof and will speed up ANY investigation significantly."
For more information about the ShadowDragon™ suite of OSINT tools and capabilities, such as SocialNet®, OIMonitor®, MalNet®, and Horizon®, click here.
About ShadowDragon
ShadowDragon™ provides comprehensive, cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open source intelligence (OSINT) from over 225 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for Good”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240413210644/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom